The relationship between elevated serum xenin and insulin resistance in women with polycystic ovary syndrome: a case-control study

References

• Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet. 2007;370:685–697.
   PubMed Web of Science ®Google Scholar
• Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6–15.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
   PubMed Web of Science ®Google Scholar
• Feurle GE, Hamscher G, Kusiek R, et al. Identification of xenin, a xenopsin-related peptide, in the human gastric mucosa and its effect on exocrine pancreatic secretion. J Biol Chem. 1992;267:22305–22309.
   PubMed Web of Science ®Google Scholar
• Kaji I, Akiba Y, Kato I, et al. Xenin augments duodenal anion secretion via activation of afferent neural pathways. J Pharmacol Exp Ther. 2017;361:151–161.
   PubMed Web of Science ®Google Scholar
• Feurle GE, Ikonomu S, Partoulas G, et al. Xenin plasma concentrations during modified sham feeding and during meals of different composition demonstrated by radioimmunoassay and chromatography. Regul Pept. 2003;111:153–159.
   PubMedGoogle Scholar
• Parthsarathy V, Irwin N, Hasib A, et al. A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties. Biochim Biophys Acta. 2016;1860:757–764.
   PubMed Web of Science ®Google Scholar
• Holst JJ, Knop FK, Vilsboll T, et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34:S251–S257.
   PubMed Web of Science ®Google Scholar
• Craig SL, Gault VA, Irwin N. Emerging therapeutic potential for xenin and related peptides in obesity and diabetes. Diabetes Metab Res Rev. 2018;34:e3006.
   PubMed Web of Science ®Google Scholar
• Bhavya S, Lew PS, Mizuno TM. Stimulation of white adipose tissue lipolysis by xenin, a neurotensin-related peptide. Biochem Biophys Res Commun. 2018;498:842–848.
   PubMed Web of Science ®Google Scholar
• Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:1623–1627.
   Web of Science ®Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
   PubMed Web of Science ®Google Scholar
• Faiman C, Ryan RJ. Serum follicle-stimulating hormone and luteinizing hormone concentrations during the menstrual cycle as determined by radioimmunoassays. J Clin Endocrinol Metab. 1967;27:1711–1716.
   PubMed Web of Science ®Google Scholar
• Arslan N, Sayin O, Tokgoz Y. Evaluation of serum xenin and ghrelin levels and their relationship with nonalcoholic fatty liver disease and insulin resistance in obese adolescents. J Endocrinol Invest. 2014;37:1091–1097.
   PubMed Web of Science ®Google Scholar
• Mrozek B, Tomasik PJ, Wedrychowicz A, et al. Plasma xenin concentrations in children. Pediatr Endocrinol Diab Metab. 2012;18:5–8.
   PubMedGoogle Scholar
• Faul F, Erdfelder E, Lang A-G, et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–191.
   PubMed Web of Science ®Google Scholar
• Temur M, Yılmaz Ö, Aksun S, et al. The relationship of urocortin-2 with insulin resistance patients having PCOS. Gynecol Endocrinol. 2017;33:124–127.
   PubMed Web of Science ®Google Scholar
• Temur M, Yilmaz Ö, Aksun S, et al. Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome. Gynecol Endocrinol. 2016;32:218–222.
   PubMed Web of Science ®Google Scholar
• Temur M, Calan M, Akşit M, et al. Increased serum neuregulin 4 levels in women with polycystic ovary syndrome: a case-control study. Ginekol Pol. 2017;88:517–522.
   PubMed Web of Science ®Google Scholar
• Yilmaz Ö, Temur M, Calan M, et al. The relationship between lipocalin-2 and free testosterone levels in polycystic ovary syndrome. Endokrynol Pol. 2017;68:7–12.
   PubMed Web of Science ®Google Scholar
• Temur M, Ozun Ozbay P, Aksun S, et al. Elevated circulating levels of xenopsin-related peptide-1 are associated with polycystic ovary syndrome. Arch Gynecol Obstet. 2017;296:841–846.
   PubMed Web of Science ®Google Scholar
• Alexiou C, Zimmermann JP, Schick RR, et al. Xenin-a novel suppressor of food intake in rats. Brain Res. 1998;800:294–299.
   PubMed Web of Science ®Google Scholar
• Stoschus B, Hamscher G, Ikonomou S, et al. Effect of omeprazole treatment on plasma concentrations of the gastric peptides, xenin, gastrin and somatostatin, and of pepsinogen. J Pept Res. 1998;52:27–33.
   PubMedGoogle Scholar
• Kerbel B, Badal K, Sundarrajan L, et al. Xenin is a novel anorexigen in goldfish (Carassius auratus). PLoS One. 2018;13:e0197817.
   PubMed Web of Science ®Google Scholar
• van de Sande-Lee S, Cardoso AR, Garlipp CR, et al. Cerebrospinal fluid xenin levels during body mass reduction: no evidence for obesity-associated defective transport across the blood-brain barrier. Int J Obes. 2013;37:416–419.
   Web of Science ®Google Scholar
• Wice BM, Reeds DN, Tran HD, et al. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. Diabetes. 2012;61:1793–1800.
   PubMed Web of Science ®Google Scholar
• Sterl K, Wang S, Oestricker L, et al. Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery. Peptides. 2016;82:76–84.
   PubMed Web of Science ®Google Scholar
• Ibanez L, Oberfield SE, Witchel S, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr. 2017;88:371–395.
   PubMed Web of Science ®Google Scholar